Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALKS

Alkermes plc

Jul 26 • 04:00PM ET

27.88

Dollar change -0.16
Percentage change -0.57	%

Healthcare • Drug Manufacturers - Specialty & Generic • Ireland • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IJR CALF VTI IWM VB XBI VXF VBK FBT IWO

Scroll to Statements

Index	RUT	P/E	16.52	EPS (ttm)	1.69	Insider Own	1.48%	Shs Outstand	166.98M	Perf Week	12.28%
Market Cap	4.72B	Forward P/E	10.73	EPS next Y	2.60	Insider Trans	-0.62%	Shs Float	166.72M	Perf Month	13.47%
Income	288.72M	PEG	0.67	EPS next Q	0.72	Inst Own	104.62%	Short Float	9.68%	Perf Quarter	14.08%
Sales	1.51B	P/S	3.13	EPS this Y	89.43%	Inst Trans	-1.26%	Short Ratio	8.43	Perf Half Y	-0.50%
Book/sh	7.74	P/B	3.60	EPS next Y	-4.76%	ROA	15.56%	Short Interest	16.13M	Perf Year	-0.20%
Cash/sh	5.18	P/C	5.38	EPS next 5Y	24.80%	ROE	26.67%	52W Range	20.46 - 32.88	Perf YTD	0.50%
Dividend Est.	-	P/FCF	14.42	EPS past 5Y	-	ROI	17.57%	52W High	-15.21%	Beta	0.45
Dividend TTM	-	Quick Ratio	2.61	Sales past 5Y	10.61%	Gross Margin	81.70%	52W Low	36.26%	ATR (14)	0.91
Dividend Ex-Date	-	Current Ratio	2.99	EPS Y/Y TTM	182.27%	Oper. Margin	16.69%	RSI (14)	75.71	Volatility	4.63% 3.18%
Employees	2100	Debt/Eq	0.29	Sales Y/Y TTM	3.14%	Profit Margin	19.15%	Recom	2.07	Target Price	34.50
Option/Short	Yes / Yes	LT Debt/Eq	0.28	EPS Q/Q	-61.34%	Payout	0.00%	Rel Volume	1.10	Prev Close	28.04
Sales Surprise	1.48%	EPS Surprise	-0.57%	Sales Q/Q	-35.35%	Earnings	Jul 24 BMO	Avg Volume	1.91M	Price	27.88
SMA20	13.75%	SMA50	14.46%	SMA200	7.97%	Trades		Volume	2,101,791	Change	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight	$32
Dec-01-21	Initiated	Citigroup	Neutral	$22
Oct-07-21	Upgrade	Jefferies	Hold → Buy	$36
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform	$27
Oct-15-20	Upgrade	Mizuho	Neutral → Buy	$19 → $24
Jul-30-20	Downgrade	Goldman	Neutral → Sell	$19 → $15
Feb-14-20	Reiterated	H.C. Wainwright	Neutral	$26 → $25
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral	$21
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral	$31 → $20

Show Previous Ratings

Today 12:40PM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
Jul-25-24 10:44AM	Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat (Zacks) +5.77%
Jul-24-24 09:30AM	Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +6.04%
08:15AM	Alkermes (ALKS) Lags Q2 Earnings Estimates (Zacks)
07:21AM	Alkermes: Q2 Earnings Snapshot (Associated Press Finance)
07:18AM	Loading…
07:18AM	Alkermes Reiterates FY24 Revenue Outlook - Update (RTT News)
07:00AM	Alkermes plc Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-17-24 04:00PM	Alkermes to Report Second Quarter Financial Results on July 24, 2024 (PR Newswire)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jun-04-24 08:30AM	Alkermes impresses in full-throttle narcolepsy race with Takeda (FierceBiotech.com)
Jun-03-24 07:00AM	Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 (PR Newswire)
May-31-24 11:31AM	Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report? (Zacks)
May-29-24 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
May-28-24 07:00AM	Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 (PR Newswire)
May-25-24 12:00PM	3 Biotech Stocks That Could Be Millionaire-Makers: May Edition (InvestorPlace)
08:48AM	Loading…
May-21-24 08:48AM	Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? (Zacks)
May-14-24 07:00AM	Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences (PR Newswire)
May-02-24 11:39AM	Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
11:15AM	UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating (MT Newswires)
07:00AM	Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk (PR Newswire)
May-01-24 11:54AM	ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:07AM	Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:36AM	Alkermes's Q1 Earnings, Revenue Grow But Miss Street View (MT Newswires)
09:30AM	Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:30AM	Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates (Zacks)
07:26AM	Alkermes: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-30-24 08:00AM	How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits? (Investor's Business Daily)
Apr-24-24 07:00AM	Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 (PR Newswire)
Apr-22-24 02:14PM	Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? (Zacks)
04:00PM	Loading…
Apr-17-24 04:00PM	Alkermes to Report First Quarter Financial Results on May 1, 2024 (PR Newswire)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-11-24 10:15AM	Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study (Zacks)
10:00AM	Alkermes' Innovations Are Transforming Mental Health Treatments (GuruFocus.com)
Apr-10-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Apr-09-24 12:38PM	BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024 (Associated Press Finance)
07:00AM	Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia (PR Newswire)
Apr-08-24 07:00AM	Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society (PR Newswire)
Apr-02-24 12:10PM	Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again (Zacks)
Mar-18-24 07:01PM	Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS) (GuruFocus.com)
Mar-15-24 06:15PM	Alkermes (ALKS) Stock Moves -0.45%: What You Should Know (Zacks)
Mar-13-24 12:45PM	3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock (Zacks)
Mar-12-24 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks)
Mar-10-24 10:00AM	10 Alternatives to Antidepressant Medications (Insider Monkey)
Mar-08-24 09:45AM	Here's Why Alkermes (ALKS) is a Strong Growth Stock (Zacks)
Mar-07-24 06:15PM	Why Alkermes (ALKS) Outpaced the Stock Market Today (Zacks)
07:00AM	Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors (PR Newswire)
Feb-29-24 06:15PM	Alkermes (ALKS) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Feb-23-24 09:50AM	Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term (Zacks)
Feb-21-24 09:45AM	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term (Zacks)
Feb-16-24 10:18AM	Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 02:40PM	Alkermes Stock Gets RS Rating Upgrade; Profits Surge (Investor's Business Daily) +16.33%
01:34PM	Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates (Zacks)
09:30AM	Compared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key Metrics (Zacks)
07:37AM	Alkermes PLC (ALKS) Reports Strong 2023 Financial Results and Sets Positive Outlook for 2024 (GuruFocus.com)
07:30AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 (PR Newswire)
Feb-12-24 09:16AM	Exploring Analyst Estimates for Alkermes (ALKS) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-08-24 04:10PM	7 Biotech Stocks Fighting Americas Deadliest Diseases (InvestorPlace)
04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 (PR Newswire)
10:00AM	Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-07-24 06:15PM	Alkermes (ALKS) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Feb-02-24 02:15AM	The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 (InvestorPlace)
Feb-01-24 06:15PM	Alkermes (ALKS) Stock Dips While Market Gains: Key Facts (Zacks)
05:00PM	3 Top Pharma Stocks to Buy Now: February 2024 (InvestorPlace)
Jan-30-24 12:10PM	Why Alkermes (ALKS) Could Beat Earnings Estimates Again (Zacks)
Jan-26-24 06:15PM	Alkermes (ALKS) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
Jan-12-24 06:15PM	Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jan-03-24 04:00PM	Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
07:00AM	Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI (olanzapine and samidorphan) (PR Newswire)
Dec-27-23 11:45AM	Equal Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes (ACCESSWIRE)
Dec-22-23 06:15PM	Alkermes (ALKS) Outperforms Broader Market: What You Need to Know (Zacks)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
12:15PM	Corporate Governance at Alkermes (ACCESSWIRE)
Dec-18-23 01:45PM	Alkermes' Commitment to Integrity and Compliance (ACCESSWIRE)
Dec-14-23 10:45AM	Alkermes' Culture of Employee Engagement and Wellness (ACCESSWIRE)
06:05AM	Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk (PR Newswire)
Dec-13-23 04:08AM	12 Best Growth Stocks to Buy According to Billionaire Ray Dalios Bridgewater Associates (Insider Monkey)
Dec-11-23 02:30PM	Patient Advocacy and Community Engagement at Alkermes (ACCESSWIRE)
Dec-01-23 06:16PM	Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire) +8.40%
Nov-29-23 03:15PM	Pharmaceuticals in the Environment (ACCESSWIRE)
Nov-24-23 11:31AM	Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report? (Zacks)
Nov-21-23 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
11:45AM	Environmental Protection & Sustainability at Alkermes (ACCESSWIRE)
Nov-20-23 01:45PM	Alkermes Celebrates #Movember for Mens Health Awareness Month (ACCESSWIRE)
Nov-16-23 10:30AM	Alkermes' Waste Optimization Highlights (ACCESSWIRE) +6.03%
Nov-15-23 08:57AM	Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout (FierceBiotech.com)
07:15AM	Alkermes separates cancer drug business as new company Mural (BioPharma Dive)
07:00AM	Alkermes Completes Separation of Oncology Business (PR Newswire)
Nov-14-23 01:45PM	Our Commitment to Caregivers (ACCESSWIRE)
10:33AM	Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition (Zacks)
05:50AM	3 Growth Stocks Set to Dominate the Decade (InvestorPlace)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
12:45PM	Product Stewardship and Environmental Impact at Alkermes (ACCESSWIRE)
Nov-10-23 03:00PM	Caring for Caregivers: Alkermes Celebrates National Caregivers Month (ACCESSWIRE)
Nov-09-23 11:12AM	7 Healthcare Stocks That Are Poised to Become the Next Unicorns (InvestorPlace)
Nov-08-23 11:30AM	Environmental Health and Safety at Alkermes (ACCESSWIRE)
Nov-07-23 04:00PM	Alkermes to Participate in the Jefferies London Healthcare Conference (PR Newswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nichols Christian Todd	SVP, Chief Commercial Officer	Mar 18 '24	Sale	28.10	10,417	292,740	65,911	Mar 18 04:02 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 27 '24	Sale	29.65	2,559	75,874	7,717	Feb 27 04:09 PM
LAURENCIN CATO T	Director	Feb 15 '24	Option Exercise	22.52	2,690	60,579	17,859	Feb 16 04:01 PM
LAURENCIN CATO T	Director	Feb 15 '24	Sale	31.85	2,690	85,676	15,169	Feb 16 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALKS

Alkermes plc

Upgrade your FINVIZ experience